Histone H3.3 Mutations: A Variant Path to Cancer

Cancer Cell

Volumn 24, Issue 5, 2013, Pages 567-574

  Yuen, Benjamin T K ^a,b   Knoepfler, Paul S ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CENTROMERE PROTEIN A; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HISTONE DEMETHYLASE; HISTONE H3; K RAS PROTEIN; TRANSCRIPTION FACTOR EZH2;

ASTROCYTE; BRAIN DEVELOPMENT; CARCINOGENESIS; CELL DIFFERENTIATION; CELL NUCLEUS TRANSPLANTATION; CELL PROLIFERATION; CHROMATIN; CHROMATIN CONDENSATION; CHROMOSOME SEGREGATION; CONFORMATIONAL TRANSITION; DNA METHYLATION; DROSOPHILA MELANOGASTER; EMBRYO DEVELOPMENT; EPIGENETICS; EUCHROMATIN; GENETIC VARIABILITY; GENOMIC INSTABILITY; GERM CELL; HEMISPHERE; HISTONE MODIFICATION; HOMOLOGOUS RECOMBINATION; LOSS OF FUNCTION MUTATION; MUTATIONAL ANALYSIS; NEURAL STEM CELL; NEUROBLASTOMA; NONHUMAN; NUCLEOSOME; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SOMATIC CELL; SOMATIC HYPERMUTATION; UNTRANSLATED REGION; UPREGULATION;

EID: 84887512911     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.09.015     Document Type: Review

References (77)

1. Ahmad K., Henikoff S. The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. Mol. Cell 2002, 9:1191-1200.
2. Aida M., Hamad N., Stanlie A., Begum N.A., Honjo T. Accumulation of the FACT complex, as well as histone H3.3, serves as a target marker for somatic hypermutation. Proc. Natl. Acad. Sci. USA 2013, 110:7784-7789.
3. Akhmanova A.S., Bindels P.C., Xu J., Miedema K., Kremer H., Hennig W. Structure and expression of histone H3.3 genes in Drosophila melanogaster and Drosophila hydei. Genome 1995, 38:586-600.
4. Albig W., Bramlage B., Gruber K., Klobeck H.G., Kunz J., Doenecke D. The human replacement histone H3.3B gene (H3F3B). Genomics 1995, 30:264-272.
5. Attieh Y., Geng Q.R., Dinardo C.D., Zheng H., Jia Y., Fang Z.H., Gañán-Gómez I., Yang H., Wei Y., Kantarjian H., Garcia-Manero G. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood 2013, 121:4009-4011.
6. Baumann C., Viveiros M.M., De La Fuente R. Loss of maternal ATRX results in centromere instability and aneuploidy in the mammalian oocyte and pre-implantation embryo. PLoS Genet. 2010, 6:e1001137.
7. Bjerke L., Mackay A., Nandhabalan M., Burford A., Jury A., Popov S., Bax D.A., Carvalho D., Taylor K.R., Vinci M., et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 2013, Mar 28. [Epub ahead of print].
8. Bracken A.P., Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 2009, 9:773-784.
9. Bush K.M., Yuen B.T., Barrilleaux B.L., Riggs J.W., O'Geen H., Cotterman R.F., Knoepfler P.S. Endogenous mammalian histone H3.3 exhibits chromatin-related functions during development. Epigenetics Chromatin 2013, 6:7.
10. Chan K.M., Fang D., Gan H., Hashizume R., Yu C., Schroeder M., Gupta N., Mueller S., James C.D., Jenkins R., et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013, 27:985-990.
11. Cheung N.K., Zhang J., Lu C., Parker M., Bahrami A., Tickoo S.K., Heguy A., Pappo A.S., Federico S., Dalton J., et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012, 307:1062-1071. St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project.
12. Cotterman R., Jin V.X., Krig S.R., Lemen J.M., Wey A., Farnham P.J., Knoepfler P.S. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res. 2008, 68:9654-9662.
13. Couldrey C., Carlton M.B., Nolan P.M., Colledge W.H., Evans M.J. A retroviral gene trap insertion into the histone 3.3A gene causes partial neonatal lethality, stunted growth, neuromuscular deficits and male sub-fertility in transgenic mice. Hum. Mol. Genet. 1999, 8:2489-2495.
14. Cox S.G., Kim H., Garnett A.T., Medeiros D.M., An W., Crump J.G. An essential role of variant histone H3.3 for ectomesenchyme potential of the cranial neural crest. PLoS Genet. 2012, 8:e1002938.
15. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
16. Delbarre E., Jacobsen B.M., Reiner A.H., Sørensen A.L., Küntziger T., Collas P. Chromatin environment of histone variant H3.3 revealed by quantitative imaging and genome-scale chromatin and DNA immunoprecipitation. Mol. Biol. Cell 2010, 21:1872-1884.
17. Delbarre E., Ivanauskiene K., Küntziger T., Collas P. DAXX-dependent supply of soluble (H3.3-H4) dimers to PML bodies pending deposition into chromatin. Genome Res. 2013, 23:440-451.
18. Drané P., Ouararhni K., Depaux A., Shuaib M., Hamiche A. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 2010, 24:1253-1265.
19. 1 phase. Nucleus 2011, 2:146-157.
20. Edmunds J.W., Mahadevan L.C., Clayton A.L. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 2008, 27:406-420.
21. Fontebasso A.M., Liu X.Y., Sturm D., Jabado N. Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. Brain Pathol. 2013, 23:210-216.
22. Fontebasso A.M., Schwartzentruber J., Khuong-Quang D.A., Liu X.Y., Sturm D., Korshunov A., Jones D.T., Witt H., Kool M., Albrecht S., et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 2013, 125:659-669.
23. Gessi M., Gielen G.H., Hammes J., Dörner E., Mühlen A.Z., Waha A., Pietsch T. H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?. J.Neurooncol. 2013, 112:67-72.
24. Goldberg A.D., Banaszynski L.A., Noh K.M., Lewis P.W., Elsaesser S.J., Stadler S., Dewell S., Law M., Guo X., Li X., et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010, 140:678-691.
25. Hake S.B., Garcia B.A., Duncan E.M., Kauer M., Dellaire G., Shabanowitz J., Bazett-Jones D.P., Allis C.D., Hunt D.F. Expression patterns and post-translational modifications associated with mammalian histone H3 variants. J.Biol. Chem. 2006, 281:559-568.
26. Heaphy C.M., de Wilde R.F., Jiao Y., Klein A.P., Edil B.H., Shi C., Bettegowda C., Rodriguez F.J., Eberhart C.G., Hebbar S., et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333:425.
27. Hock H. A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev. 2012, 26:751-755.
28. Hödl M., Basler K. Transcription in the absence of histone H3.3. Curr. Biol. 2009, 19:1221-1226.
29. Je E.M., Yoo N.J., Kim Y.J., Kim M.S., Lee S.H. Somatic mutation of H3F3A, a chromatin remodeling gene, is rare in acute leukemias and non-Hodgkin lymphoma. Eur. J. Haematol. 2013, 90:169-170.
30. Je E.M., Yoo N.J., Lee S.H. Mutational analysis of H3F3A, a chromatin remodeling gene in common solid tumors. APMIS 2013.
31. Jiao Y., Shi C., Edil B.H., de Wilde R.F., Klimstra D.S., Maitra A., Schulick R.D., Tang L.H., Wolfgang C.L., Choti M.A., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331:1199-1203.
32. Jones J.M., Bhattacharyya A., Simkus C., Vallieres B., Veenstra T.D., Zhou M. The RAG1 V(D)J recombinase/ubiquitin ligase promotes ubiquitylation of acetylated, phosphorylated histone 3.3. Immunol. Lett. 2011, 136:156-162.
33. Jones D.T., Hutter B., Jäger N., Korshunov A., Kool M., Warnatz H.J., Zichner T., Lambert S.R., Ryzhova M., Quang D.A., et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 2013, 45:927-932. International Cancer Genome Consortium PedBrain Tumor Project.
34. Jullien J., Astrand C., Szenker E., Garrett N., Almouzni G., Gurdon J.B. HIRA dependent H3.3 deposition is required for transcriptional reprogramming following nuclear transfer to Xenopus oocytes. Epigenetics Chromatin 2012, 5:17.
35. Khuong-Quang D.A., Buczkowicz P., Rakopoulos P., Liu X.Y., Fontebasso A.M., Bouffet E., Bartels U., Albrecht S., Schwartzentruber J., Letourneau L., et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012, 124:439-447.
36. Knoepfler P.S., Zhang X.Y., Cheng P.F., Gafken P.R., McMahon S.B., Eisenman R.N. Myc influences global chromatin structure. EMBO J. 2006, 25:2723-2734.
37. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40:741-750.
38. Lewis P.W., Müller M.M., Koletsky M.S., Cordero F., Lin S., Banaszynski L.A., Garcia B.A., Muir T.W., Becher O.J., Allis C.D. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
39. Lin C.J., Conti M., Ramalho-Santos M. Histone variant H3.3 maintains a decondensed chromatin state essential for mouse preimplantation development. Development 2013, 140:3624-3634.
40. Margueron R., Justin N., Ohno K., Sharpe M.L., Son J., Drury W.J., Voigt P., Martin S.R., Taylor W.R., De Marco V., et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 2009, 461:762-767.
41. McKittrick E., Gafken P.R., Ahmad K., Henikoff S. Histone H3.3 is enriched in covalent modifications associated with active chromatin. Proc. Natl. Acad. Sci. USA 2004, 101:1525-1530.
42. Mehta S., Huillard E., Kesari S., Maire C.L., Golebiowski D., Harrington E.P., Alberta J.A., Kane M.F., Theisen M., Ligon K.L., et al. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 2011, 19:359-371.
43. Meshorer E. Chromatin in embryonic stem cell neuronal differentiation. Histol. Histopathol. 2007, 22:311-319.
44. Michod D., Bartesaghi S., Khelifi A., Bellodi C., Berliocchi L., Nicotera P., Salomoni P. Calcium-dependent dephosphorylation of the histone chaperone DAXX regulates H3.3 loading and transcription upon neuronal activation. Neuron 2012, 74:122-135.
45. Ng R.K., Gurdon J.B. Epigenetic memory of an active gene state depends on histone H3.3 incorporation into chromatin in the absence of transcription. Nat. Cell Biol. 2008, 10:102-109.
46. Piña B., Suau P. Changes in histones H2A and H3 variant composition in differentiating and mature rat brain cortical neurons. Dev. Biol. 1987, 123:51-58.
47. Ray-Gallet D., Woolfe A., Vassias I., Pellentz C., Lacoste N., Puri A., Schultz D.C., Pchelintsev N.A., Adams P.D., Jansen L.E., Almouzni G. Dynamics of histone H3 deposition invivo reveal a nucleosome gap-filling mechanism for H3.3 to maintain chromatin integrity. Mol. Cell 2011, 44:928-941.
48. Riggs J.W., Barrilleaux B.L., Varlakhanova N., Bush K.M., Chan V., Knoepfler P.S. Induced pluripotency and oncogenic transformation are related processes. Stem Cells Dev. 2013, 22:37-50.
49. Ringrose L., Ehret H., Paro R. Distinct contributions of histone H3 lysine 9 and 27 methylation to locus-specific stability of polycomb complexes. Mol. Cell 2004, 16:641-653.
50. Roberts C., Sutherland H.F., Farmer H., Kimber W., Halford S., Carey A., Brickman J.M., Wynshaw-Boris A., Scambler P.J. Targeted mutagenesis of the Hira gene results in gastrulation defects and patterning abnormalities of mesoendodermal derivatives prior to early embryonic lethality. Mol. Cell. Biol. 2002, 22:2318-2328.
51. Sakai A., Schwartz B.E., Goldstein S., Ahmad K. Transcriptional and developmental functions of the H3.3 histone variant in Drosophila. Curr. Biol. 2009, 19:1816-1820.
52. Santenard A., Ziegler-Birling C., Koch M., Tora L., Bannister A.J., Torres-Padilla M.E. Heterochromatin formation in the mouse embryo requires critical residues of the histone variant H3.3. Nat. Cell Biol. 2010, 12:853-862.
53. Schenk R., Jenke A., Zilbauer M., Wirth S., Postberg J. H3.5 is a novel hominid-specific histone H3 variant that is specifically expressed in the seminiferous tubules of human testes. Chromosoma 2011, 120:275-285.
54. Schneiderman J.I., Orsi G.A., Hughes K.T., Loppin B., Ahmad K. Nucleosome-depleted chromatin gaps recruit assembly factors for the H3.3 histone variant. Proc. Natl. Acad. Sci. USA 2012, 109:19721-19726.
55. Schwartzentruber J., Korshunov A., Liu X.Y., Jones D.T., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D.A., Tönjes M., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
56. Shen X., Liu Y., Hsu Y.J., Fujiwara Y., Kim J., Mao X., Yuan G.C., Orkin S.H. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 2008, 32:491-502.
57. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
58. Sturm D., Witt H., Hovestadt V., Khuong-Quang D.A., Jones D.T., Konermann C., Pfaff E., Tönjes M., Sill M., Bender S., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012, 22:425-437.
59. Suvà M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
60. Swartling F.J., Savov V., Persson A.I., Chen J., Hackett C.S., Northcott P.A., Grimmer M.R., Lau J., Chesler L., Perry A., et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 2012, 21:601-613.
61. Szenker E., Ray-Gallet D., Almouzni G. The double face of the histone variant H3.3. Cell Res. 2011, 21:421-434.
62. Szenker E., Lacoste N., Almouzni G. A developmental requirement for HIRA-dependent H3.3 deposition revealed at gastrulation in Xenopus. Cell Rep 2012, 1:730-740.
63. Tagami H., Ray-Gallet D., Almouzni G., Nakatani Y. Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell 2004, 116:51-61.
64. Tang M.C., Jacobs S.A., Wong L.H., Mann J.R. Conditional allelic replacement applied to genes encoding the histone variant H3.3 in the mouse. Genesis 2013, 51:142-146.
65. Venneti S., Garimella M.T., Sullivan L.M., Martinez D., Huse J.T., Heguy A., Santi M., Thompson C.B., Judkins A.R. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol. 2013, 23:558-564.
66. Wagner E.J., Carpenter P.B. Understanding the language of Lys36 methylation at histone H3. Nat. Rev. Mol. Cell Biol. 2012, 13:115-126.
67. Wells D., Hoffman D., Kedes L. Unusual structure, evolutionary conservation of non-coding sequences and numerous pseudogenes characterize the human H3.3 histone multigene family. Nucleic Acids Res. 1987, 15:2871-2889.
68. Wiestler B., Claus R., Hartlieb S.A., Schliesser M.G., Weiss E.K., Hielscher T., Platten M., Dittmann L.M., Meisner C., Felsberg J., et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-oncol. 2013, 15:1017-1026. Neuro-oncology Working Group (NOA) of the German Cancer Society.
69. Witt O., Albig W., Doenecke D. Transcriptional regulation of the human replacement histone gene H3.3B. FEBS Lett. 1997, 408:255-260.
70. Wu R.S., Tsai S., Bonner W.M. Patterns of histone variant synthesis can distinguish G0 from G1 cells. Cell 1982, 31:367-374.
71. Wu G., Broniscer A., McEachron T.A., Lu C., Paugh B.S., Becksfort J., Qu C., Ding L., Huether R., Parker M., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 2012, 44:251-253. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project.
72. Xu C., Bian C., Yang W., Galka M., Ouyang H., Chen C., Qiu W., Liu H., Jones A.E., MacKenzie F., et al. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). Proc. Natl. Acad. Sci. USA 2010, 107:19266-19271.
73. Yang J.H., Song Y., Seol J.H., Park J.Y., Yang Y.J., Han J.W., Youn H.D., Cho E.J. Myogenic transcriptional activation of MyoD mediated by replication-independent histone deposition. Proc. Natl. Acad. Sci. USA 2011, 108:85-90.
74. Yang X., Li L., Liang J., Shi L., Yang J., Yi X., Zhang D., Han X., Yu N., Shang Y. Histone acetyltransferase 1 promotes homologous recombination in DNA repair by facilitating histone turnover. J.Biol. Chem. 2013, 288:18271-18282.
75. Yoo K.H., Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int. J. Biol. Sci. 2012, 8:59-65.
76. Yuan W., Xu M., Huang C., Liu N., Chen S., Zhu B. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J.Biol. Chem. 2011, 286:7983-7989.
77. Zhang J., Wu G., Miller C.P., Tatevossian R.G., Dalton J.D., Tang B., Orisme W., Punchihewa C., Parker M., Qaddoumi I., et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 2013, 45:602-612. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project.